PL3778885T3 - Kompozycje modyfikowanych ludzkich arginaz i sposoby leczenia raka - Google Patents

Kompozycje modyfikowanych ludzkich arginaz i sposoby leczenia raka

Info

Publication number
PL3778885T3
PL3778885T3 PL20171935.8T PL20171935T PL3778885T3 PL 3778885 T3 PL3778885 T3 PL 3778885T3 PL 20171935 T PL20171935 T PL 20171935T PL 3778885 T3 PL3778885 T3 PL 3778885T3
Authority
PL
Poland
Prior art keywords
compositions
methods
treating cancer
engineered human
human arginases
Prior art date
Application number
PL20171935.8T
Other languages
English (en)
Inventor
George Georgiou
Everett Stone
Original Assignee
Aerase, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aerase, Inc. filed Critical Aerase, Inc.
Publication of PL3778885T3 publication Critical patent/PL3778885T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/03—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amidines (3.5.3)
    • C12Y305/03001—Arginase (3.5.3.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
PL20171935.8T 2008-10-31 2009-11-02 Kompozycje modyfikowanych ludzkich arginaz i sposoby leczenia raka PL3778885T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11021808P 2008-10-31 2008-10-31

Publications (1)

Publication Number Publication Date
PL3778885T3 true PL3778885T3 (pl) 2023-07-03

Family

ID=42129584

Family Applications (3)

Application Number Title Priority Date Filing Date
PL16163214T PL3064579T3 (pl) 2008-10-31 2009-11-02 Kompozycje farmaceutyczne i zastosowania medyczne uzyskanych metodami inżynierii ludzkich arginaz
PL20171935.8T PL3778885T3 (pl) 2008-10-31 2009-11-02 Kompozycje modyfikowanych ludzkich arginaz i sposoby leczenia raka
PL09824219.1T PL2350273T3 (pl) 2008-10-31 2009-11-02 Kompozycje modyfikowanych ludzkich arginaz i sposoby leczenia nowotworu złośliwego

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL16163214T PL3064579T3 (pl) 2008-10-31 2009-11-02 Kompozycje farmaceutyczne i zastosowania medyczne uzyskanych metodami inżynierii ludzkich arginaz

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL09824219.1T PL2350273T3 (pl) 2008-10-31 2009-11-02 Kompozycje modyfikowanych ludzkich arginaz i sposoby leczenia nowotworu złośliwego

Country Status (15)

Country Link
US (8) US8440184B2 (pl)
EP (5) EP3778885B1 (pl)
JP (2) JP5695570B2 (pl)
CA (1) CA2742497C (pl)
DK (3) DK3064579T3 (pl)
ES (3) ES2945580T3 (pl)
FI (1) FI3778885T3 (pl)
HR (1) HRP20230484T1 (pl)
HU (1) HUE062354T2 (pl)
LT (1) LT3778885T (pl)
PL (3) PL3064579T3 (pl)
PT (1) PT3778885T (pl)
SI (1) SI3778885T1 (pl)
SM (1) SMT202300162T1 (pl)
WO (1) WO2010051533A2 (pl)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3064579T3 (pl) * 2008-10-31 2021-07-05 Aerase, Inc. Kompozycje farmaceutyczne i zastosowania medyczne uzyskanych metodami inżynierii ludzkich arginaz
CA2766039A1 (en) * 2009-06-29 2011-01-20 The Board Of Regents Of The University Of Texas System Arginase formulations and methods
WO2012061015A2 (en) * 2010-11-03 2012-05-10 Scott & White Healthcare L-citrulline supplementation during arginine depletion therapy with arginase
CN102234624B (zh) * 2011-04-25 2013-03-06 武汉远大弘元股份有限公司 一种表达产生枯草芽孢杆菌精氨酸酶的基因工程菌及构建方法
CN103184209B (zh) * 2011-12-27 2015-09-16 拜奥生物科技(上海)有限公司 人精氨酸酶和聚乙二醇化人精氨酸酶及其应用
US9011845B2 (en) 2012-06-26 2015-04-21 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Methods for treatment of inflammatory and infectious viral diseases
US8877183B2 (en) 2012-06-26 2014-11-04 National Institutes Of Health (Nih) Methods for treatment of ocular diseases
US11357857B2 (en) 2014-06-20 2022-06-14 Comera Life Sciences, Inc. Excipient compounds for protein processing
WO2015196091A1 (en) 2014-06-20 2015-12-23 Reform Biologics, Llc Viscosity-reducing excipient compounds for protein formulations
US10478498B2 (en) 2014-06-20 2019-11-19 Reform Biologics, Llc Excipient compounds for biopolymer formulations
TWI790481B (zh) 2014-07-08 2023-01-21 開曼群島商瑞華藥業集團 精胺琥珀酸合成酶之抗體及相關方法
ES2909556T3 (es) 2016-08-08 2022-05-09 Aerase Inc Composiciones y procedimientos para el tratamiento de cáncer con agentes de disminución de arginina y de inmunoncología
PL3522905T3 (pl) * 2016-10-07 2025-01-07 Io Biotech Aps Immunogenne peptydy arginazowe
WO2018167780A1 (en) 2017-03-12 2018-09-20 Yeda Research And Development Co. Ltd. Methods of prognosing and treating cancer
WO2018167778A1 (en) 2017-03-12 2018-09-20 Yeda Research And Development Co. Ltd. Methods of diagnosing and prognosing cancer
TWI922426B (zh) 2017-08-16 2026-04-21 香港商鎧耀波麗堂(香港)有限公司 用於胺基酸耗竭治療之組合物的用途
TWI878212B (zh) * 2017-12-05 2025-04-01 瑞典商伊梅爾迪卡製藥公司 用於治療精胺酸酶1缺乏症之方法及組合物
WO2020009740A2 (en) 2018-04-25 2020-01-09 Washington University Compositions and methods of use thereof for treatment of metabolic diseases and related disorders
CN112513099A (zh) 2018-05-31 2021-03-16 香港理工大学 用于癌症、肥胖症、代谢紊乱和相关并发症及合并症的精氨酸耗竭剂的组合物和应用
GB201815549D0 (en) 2018-09-24 2018-11-07 Io Biotech Aps Arginase1 polypeptides
WO2020081994A1 (en) 2018-10-19 2020-04-23 Aerase, Inc. Arginine depletion therapy for treatment of gamt deficiency
GB201818576D0 (en) * 2018-11-14 2018-12-26 Io Biotech Aps Arginase 2 polypeptides
BR112022003633A2 (pt) * 2019-08-30 2022-06-07 Aeglea Biotherapeutics Inc Métodos para produção de arginase 1 recombinante humana e usos da mesma
WO2022195629A1 (en) * 2021-03-18 2022-09-22 National Institute Of Pharmaceutical Education And Research (Niper) Engineered arginase constructs, method of generation and uses thereof
WO2023041758A1 (en) * 2021-09-20 2023-03-23 Kyon Biotech Ag Arginase-insulin fusion protein

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02117383A (ja) * 1988-10-26 1990-05-01 Tosoh Corp ヒトアルギナーゼの製造方法
US5780286A (en) * 1996-03-14 1998-07-14 Smithkline Beecham Corporation Arginase II
WO2003063780A2 (en) * 2002-01-25 2003-08-07 Cancer Treatments International Therapeutic composition for treatment of cancer by arginine depletion
HK1053577A2 (en) 2002-06-20 2003-10-10 Bio-Cancer Treatment International Limited Pharmaceutical composition and method of treatment of human malignanices with arginine deprivation
CN1745847A (zh) * 2004-09-08 2006-03-15 康达医药科技有限公司 用精氨酸酶治疗肝炎的药物组合物和方法
PL3064579T3 (pl) * 2008-10-31 2021-07-05 Aerase, Inc. Kompozycje farmaceutyczne i zastosowania medyczne uzyskanych metodami inżynierii ludzkich arginaz

Also Published As

Publication number Publication date
FI3778885T3 (fi) 2023-05-23
SI3778885T1 (sl) 2023-07-31
EP3957727A1 (en) 2022-02-23
HK1160165A1 (zh) 2012-08-10
USRE46423E1 (en) 2017-06-06
EP3064579B1 (en) 2020-09-30
DK2350273T3 (en) 2016-06-13
WO2010051533A3 (en) 2010-08-19
EP3778885A1 (en) 2021-02-17
PL3064579T3 (pl) 2021-07-05
ES2945580T3 (es) 2023-07-04
WO2010051533A2 (en) 2010-05-06
US20140242060A1 (en) 2014-08-28
LT3778885T (lt) 2023-06-12
CA2742497C (en) 2024-01-23
EP3957728A1 (en) 2022-02-23
US20170128553A1 (en) 2017-05-11
US20240009283A1 (en) 2024-01-11
ES2574139T3 (es) 2016-06-15
EP2350273A4 (en) 2012-06-27
JP2012507301A (ja) 2012-03-29
US10098933B2 (en) 2018-10-16
ES2838848T3 (es) 2021-07-02
US20100111925A1 (en) 2010-05-06
US20130273022A1 (en) 2013-10-17
US9050340B2 (en) 2015-06-09
DK3778885T3 (da) 2023-05-30
CA2742497A1 (en) 2010-05-06
HRP20230484T1 (hr) 2023-07-21
DK3778885T5 (da) 2024-08-19
EP3778885B1 (en) 2023-03-08
JP2014036676A (ja) 2014-02-27
US20210128703A1 (en) 2021-05-06
PL2350273T3 (pl) 2016-10-31
US20190000939A1 (en) 2019-01-03
EP3064579A1 (en) 2016-09-07
EP2350273A2 (en) 2011-08-03
EP2350273B1 (en) 2016-04-06
PT3778885T (pt) 2023-05-31
DK3064579T3 (da) 2020-12-21
HUE062354T2 (hu) 2023-10-28
JP5695570B2 (ja) 2015-04-08
US8440184B2 (en) 2013-05-14
SMT202300162T1 (it) 2023-07-20

Similar Documents

Publication Publication Date Title
SI3778885T1 (sl) Sestavki inženirskih humanih arginaz in metode za zdravljenje raka
PL2340042T3 (pl) Sposoby i kompozycje do leczenia raka
ZA201006988B (en) Method and compositions for treatment of cancer
IL218987A0 (en) Methods and compositions for treating cancer
IL206970A0 (en) Compositions and methods for the treatment of tumor of hematopoietic origin
PT2200431T (pt) Novos métodos e composições para o tratamento do cancro
PL2322221T3 (pl) Kompozycja farmaceutyczna do leczenia i zapobiegania raka
SG10201510152RA (en) Diagnostic methods and compositions for treatment of cancer
IL214255A0 (en) Methods and compositions for diagnosis and treatment of cancer
EP2384198A4 (en) PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING NEUROLOGICAL INJURIES
IL236516A0 (en) Methods and preparations for the diagnosis and treatment of cancer
IL214349A0 (en) Compositions and methods for the treatment of cancer
EP2176406A4 (en) COMPOSITIONS AND METHOD FOR CANCER TREATMENT
PL2305300T3 (pl) Kompozycja farmaceutyczna do leczenia i zapobiegania nowotworowi
EP2515652A4 (en) COMPOSITIONS AND METHODS FOR TREATING VITILIGO
PT3067054T (pt) Novas composições e métodos para o tratamento de cancro
SI3067054T1 (sl) Novi sestavki in postopki za zdravljenje raka